Trials / Completed
CompletedNCT00080405
Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the clinical pharmacokinetic and pharmacodynamic profiles of the 2 doses of VELCADE (bortezomib) for Injection. Patients who volunteer to participate in the pharmacogenetic portion of the study, an additional blood sample will be collected before the Cycle 1 Day 1 dose of bortezomib to assess the genotype of drug metabolizing enzymes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bortezomib |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2005-06-01
- First posted
- 2004-04-02
- Last updated
- 2009-03-27
Source: ClinicalTrials.gov record NCT00080405. Inclusion in this directory is not an endorsement.